Leponex

Clozapine, the active ingredient in Leponex, is a atypical antipsychotic presented as an oral formulation for oral use. It is indicated for treatment‑resistant schizophrenia, schizoaffective disorder, and for reducing suicidal behavior in patients with schizophrenia.

GNH USA supplies Leponex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clozapine is an atypical antipsychotic used in the management of severe psychotic disorders that have not responded to other therapies.

- Treatment‑resistant schizophrenia: improves psychotic symptoms when other antipsychotics have failed. - Schizoaffective disorder: stabilises both mood and psychotic components of the illness. - Reduction of suicidal behavior in schizophrenia: lowers the risk of suicide in affected patients.

Clozapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness. - Weight gain and increased appetite. - Excessive salivation (hypersalivation). - Constipation. - Dizziness or orthostatic hypotension. - Tachycardia.

Serious or Rare Side Effects: - Agranulocytosis (dangerously low white‑blood‑cell count). - Myocarditis or cardiomyopathy. - Seizures, especially at higher plasma concentrations. - Neuroleptic malignant syndrome. - Severe metabolic disturbances (hyperglycaemia, dyslipidaemia). - Life‑threatening infections due to immune suppression.

Before initiating clozapine therapy, several safety measures should be observed.

- Monitor blood counts: perform regular CBCs to detect agranulocytosis early. - Assess cardiac function: baseline ECG and periodic monitoring for myocarditis. - Evaluate metabolic parameters: track weight, glucose and lipid levels. - Review concomitant medications: avoid strong CYP1A2 inhibitors without dose adjustment. - Educate patients: inform about signs of infection, fever or cardiac symptoms. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Clozapine interacts with several drugs that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Carbamazepine: induces metabolism, markedly reducing clozapine levels. - Fluvoxamine: strong CYP1A2 inhibition, leading to potentially toxic clozapine concentrations. - Smoking cessation: loss of nicotine‑induced CYP1A2 activity can raise clozapine levels.

Moderate Interactions (Monitor Closely): - Ciprofloxacin and other fluoroquinolones: moderate CYP1A2 inhibition. - QT‑prolonging agents: additive risk of cardiac arrhythmias. - Antihypertensives: enhanced hypotensive effect. - Anticholinergic drugs: may worsen constipation and cognitive effects. - Lithium: increased risk of neurotoxicity.